<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02056392</url>
  </required_header>
  <id_info>
    <org_study_id>D1532C00071</org_study_id>
    <nct_id>NCT02056392</nct_id>
  </id_info>
  <brief_title>To Assess the Effects of Single Oral Dose of Selumetinib [AZD6244; ARRY-142886] [Hyd-Sulfate]), on QTc Interval in Healthy Male Volunteers</brief_title>
  <official_title>A Phase I, Double-blind (Selumetinib [AZD6244; ARRY-142886] [Hyd-Sulfate]), Placebo-controlled, Open-Label (Moxifloxacin) Positive-controlled, Randomized, Three-period Crossover Study to Assess the Effects of Single Oral Dose of Selumetinib (75 mg) on QTc Interval Compared to Placebo, Using AVELOX (Moxifloxacin) as a Positive Control, in Healthy Male Volunteers Aged 18 to 45 Years</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AstraZeneca</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AstraZeneca</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Study to assess the effect of Selumetinib [AZD6244; ARRY-142886] [Hyd-Sulfate]), on QTc
      interval in healthy male volunteers.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A double-blind (Selumetinib [AZD6244; ARRY-142886] [Hyd-Sulfate]), Placebo-controlled,
      Open-Label (Moxifloxacin) Positive-controlled, Randomized, Three-period Crossover Study to
      Assess the Effects of Single Oral Dose of Selumetinib (75 mg) on QTc Interval Compared to
      Placebo, using AVELOX (Moxifloxacin) as a Positive Control, in Healthy Male Volunteers
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2014</start_date>
  <completion_date type="Actual">August 2014</completion_date>
  <primary_completion_date type="Actual">August 2014</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change From Baseline in QTcF</measure>
    <time_frame>30 min</time_frame>
    <description>Change from baseline in QTcF at 30 minutes (msec)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change From Baseline in QTcF</measure>
    <time_frame>1 hour</time_frame>
    <description>Change from baseline in QTcF at 1 hour (msec)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change From Baseline in QTcF</measure>
    <time_frame>1 hour 30 min</time_frame>
    <description>Change from baseline in QTcF at 1 hour 30 min (msec)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change From Baseline in QTcF</measure>
    <time_frame>2 hours</time_frame>
    <description>Change from baseline in QTcF at 2 hours (msec)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change From Baseline in QTcF</measure>
    <time_frame>3 hours</time_frame>
    <description>Change from baseline in QTcF at 3 hours (msec)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change From Baseline in QTcF</measure>
    <time_frame>4 hours</time_frame>
    <description>Change from baseline in QTcF at 4 hours (msec)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change From Baseline in QTcF</measure>
    <time_frame>6 hours</time_frame>
    <description>Change from baseline in QTcF at 6 hours (msec)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change From Baseline in QTcF</measure>
    <time_frame>8 hours</time_frame>
    <description>Change from baseline in QTcF at 8 hours (msec)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change From Baseline in QTcF</measure>
    <time_frame>12 hours</time_frame>
    <description>Change from baseline in QTcF at 12 hours (msec)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change From Baseline in QTcF</measure>
    <time_frame>24 hours</time_frame>
    <description>Change from baseline in QTcF at 24 hours (msec)</description>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">54</enrollment>
  <condition>Solid Tumours</condition>
  <arm_group>
    <arm_group_label>Selumetinib 75mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Volunteers will receive selumetinib 75mg administered by mouth, as a capsule</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Moxifloxacin 400 mg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Volunteers will receive moxifloxacin 400mg administered by mouth, as a capsule</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Selumetinib 75mg placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Volunteers will receive selumetinib 75mg placebo, administered by mouth, as a capsule.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Selumetinib</intervention_name>
    <description>Volunteers will receive 75 mg selumetinib oral dose (Treatment A)</description>
    <arm_group_label>Selumetinib 75mg</arm_group_label>
    <other_name>AZD6244</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Moxifloxacin</intervention_name>
    <description>Volunteers will receive 400 mg Moxifloxacin oral dose (Treatment B)</description>
    <arm_group_label>Moxifloxacin 400 mg</arm_group_label>
    <other_name>AveloxÂ®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>selumetinib placebo</intervention_name>
    <description>Volunteers will receive selumetinib placebo oral dose (Treatment C)</description>
    <arm_group_label>Selumetinib 75mg placebo</arm_group_label>
    <other_name>AZD6244 placebo</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria: 1. Have a body mass index (BMI) between 18 and 30 kg/m2 and weigh at
        least 50 kg and no more than 100 kg (inclusive). 2. Must have not smoked in the last 30
        days prior to screening for this study. 3. Have a calculated creatinine clearance (CrCL)
        greater than 50 mL/min using the Cockcroft-Gault formula.

        Exclusion Criteria: 1. Subjects of Japanese or non-Japanese Asian ethnicity. 2. Subjects
        where any one parent or grandparent (maternal or paternal) is Japanese or non-Japanese
        Asian (e.g. China, Taiwan, Korea, Philippines, Thailand, Vietnam, and Malaysia). Asian
        Indians are acceptable. 3. Past history of central serous retinopathy or retinal vein
        thrombosis,intraocular pressure greater than 21 mmHg or uncontrolled glaucoma. 4. Any
        clinically relevant abnormal findings in physical examination, hematology, clinical
        chemistry, urinalysis, vital signs or ECG at baseline in the opinion of the investigator.
        5. History or presence of any clinically significant disease or disorder in the opinion of
        the investigator.
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Scott Rasmussen, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Quintiles 6700 W 115th Street, Kansas, US</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Overland Park</city>
        <state>Kansas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 5, 2014</study_first_submitted>
  <study_first_submitted_qc>February 5, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 6, 2014</study_first_posted>
  <results_first_submitted>July 31, 2015</results_first_submitted>
  <results_first_submitted_qc>October 7, 2015</results_first_submitted_qc>
  <results_first_posted type="Estimate">November 9, 2015</results_first_posted>
  <last_update_submitted>October 7, 2015</last_update_submitted>
  <last_update_submitted_qc>October 7, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 9, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Phase I, healthy, pharmacokinetics</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Moxifloxacin</mesh_term>
    <mesh_term>Fluoroquinolones</mesh_term>
    <mesh_term>Norgestimate, ethinyl estradiol drug combination</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Selumetinib/Moxifloxacin/Selumetinib Placebo</title>
        </group>
        <group group_id="P2">
          <title>Moxifloxacin/Selumetinib/Selumetinib Placebo</title>
        </group>
        <group group_id="P3">
          <title>Moxifloxacin/Selumetinib Placebo/Selumetinib</title>
        </group>
        <group group_id="P4">
          <title>Selumetinib Placebo/Moxifloxacin/Selumetinib</title>
        </group>
        <group group_id="P5">
          <title>Selumetinib Placebo/Selumetinib/Moxifloxacin</title>
        </group>
        <group group_id="P6">
          <title>Selumetinib/Selumetinib Placebo/Moxifloxacin</title>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="9"/>
                <participants group_id="P3" count="9"/>
                <participants group_id="P4" count="9"/>
                <participants group_id="P5" count="8"/>
                <participants group_id="P6" count="9"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="8"/>
                <participants group_id="P3" count="6"/>
                <participants group_id="P4" count="9"/>
                <participants group_id="P5" count="7"/>
                <participants group_id="P6" count="9"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="3"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="1"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="1"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Selumetinib/Moxifloxacin/Selumetinib Placebo</title>
        </group>
        <group group_id="B2">
          <title>Moxifloxacin/Selumetinib/Selumetinib Placebo</title>
        </group>
        <group group_id="B3">
          <title>Moxifloxacin/Selumetinib Placebo/Selumetinib</title>
        </group>
        <group group_id="B4">
          <title>Selumetinib Placebo/Moxifloxacin/Selumetinib</title>
        </group>
        <group group_id="B5">
          <title>Selumetinib Placebo/Selumetinib/Moxifloxacin</title>
        </group>
        <group group_id="B6">
          <title>Selumetinib/Selumetinib Placebo/Moxifloxacin</title>
        </group>
        <group group_id="B7">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="10"/>
            <count group_id="B2" value="9"/>
            <count group_id="B3" value="9"/>
            <count group_id="B4" value="9"/>
            <count group_id="B5" value="8"/>
            <count group_id="B6" value="9"/>
            <count group_id="B7" value="54"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="26" spread="7"/>
                    <measurement group_id="B2" value="25" spread="5"/>
                    <measurement group_id="B3" value="25" spread="4"/>
                    <measurement group_id="B4" value="31" spread="8"/>
                    <measurement group_id="B5" value="28" spread="8"/>
                    <measurement group_id="B6" value="30" spread="9"/>
                    <measurement group_id="B7" value="27" spread="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="9"/>
                    <measurement group_id="B4" value="9"/>
                    <measurement group_id="B5" value="8"/>
                    <measurement group_id="B6" value="9"/>
                    <measurement group_id="B7" value="54"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>White</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="4"/>
                    <measurement group_id="B4" value="4"/>
                    <measurement group_id="B5" value="5"/>
                    <measurement group_id="B6" value="4"/>
                    <measurement group_id="B7" value="29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Black or African American</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="5"/>
                    <measurement group_id="B4" value="5"/>
                    <measurement group_id="B5" value="3"/>
                    <measurement group_id="B6" value="5"/>
                    <measurement group_id="B7" value="25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in QTcF</title>
        <description>Change from baseline in QTcF at 30 minutes (msec)</description>
        <time_frame>30 min</time_frame>
        <population>All patients who had evaluable pharmacodynamic data available for at least one treatment group were included in the PD analysis set</population>
        <group_list>
          <group group_id="O1">
            <title>Moxifloxacin</title>
            <description>Moxiflxacin 400 mg (open label)</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Selumetinib placebo (3 capsules)</description>
          </group>
          <group group_id="O3">
            <title>Selumetinib</title>
            <description>Selumetinib 75mg bs (3x25mg capsules)</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in QTcF</title>
          <description>Change from baseline in QTcF at 30 minutes (msec)</description>
          <population>All patients who had evaluable pharmacodynamic data available for at least one treatment group were included in the PD analysis set</population>
          <units>msec</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <units_analyzed>Participants</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="50"/>
                <count group_id="O2" value="49"/>
                <count group_id="O3" value="50"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>change from baseline</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="50"/>
                <count group_id="O2" value="49"/>
                <count group_id="O3" value="50"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.0" lower_limit="0.5" upper_limit="3.5"/>
                    <measurement group_id="O2" value="-4.1" lower_limit="-5.6" upper_limit="-2.5"/>
                    <measurement group_id="O3" value="-4.2" lower_limit="-5.7" upper_limit="-2.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>47 evaluable volunteers gives 90% power to show non-inferiority of selumetinib versus placebo across all 10 post-dose time points, using paired T-test, 1-sided alpha=0.05 and assuming a true difference of 3 msec.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>All one-sided 95% confidence intervals at each time point for the selumetinib difference versus placebo (2-sided 90% CIs) should be less than 10ms.</non_inferiority_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.2</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.8</ci_lower_limit>
            <ci_upper_limit>1.5</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>47 evaluable volunteers gives 90% power to show non-inferiority of selumetinib versus placebo across all 10 post-dose time points, using paired T-test, 1-sided alpha=0.05 and assuming a true difference of 3 msec.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>All one-sided 95% confidence intervals at each time point for the selumetinib difference versus placebo (2-sided 90% CIs) should be less than 10ms.</non_inferiority_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>6.1</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>4.4</ci_lower_limit>
            <ci_upper_limit>7.7</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in QTcF</title>
        <description>Change from baseline in QTcF at 1 hour (msec)</description>
        <time_frame>1 hour</time_frame>
        <population>All patients who had evaluable pharmacodynamic data available for at least one treatment group were included in the PD analysis set</population>
        <group_list>
          <group group_id="O1">
            <title>Moxifloxacin</title>
            <description>Moxiflxacin 400 mg (open label)</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Selumetinib placebo (3 capsules)</description>
          </group>
          <group group_id="O3">
            <title>Selumetinib</title>
            <description>Selumetinib 75mg bs (3x25mg capsules)</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in QTcF</title>
          <description>Change from baseline in QTcF at 1 hour (msec)</description>
          <population>All patients who had evaluable pharmacodynamic data available for at least one treatment group were included in the PD analysis set</population>
          <units>msec</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <units_analyzed>Participants</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="50"/>
                <count group_id="O2" value="49"/>
                <count group_id="O3" value="50"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>change from baseline</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="50"/>
                <count group_id="O2" value="49"/>
                <count group_id="O3" value="50"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.9" lower_limit="6.4" upper_limit="9.4"/>
                    <measurement group_id="O2" value="-1.4" lower_limit="-2.9" upper_limit="0.2"/>
                    <measurement group_id="O3" value="-1.7" lower_limit="-3.2" upper_limit="-0.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>47 evaluable volunteers gives 90% power to show non-inferiority of selumetinib versus placebo across all 10 post-dose time points, using paired T-test, 1-sided alpha=0.05 and assuming a true difference of 3 msec.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>All one-sided 95% confidence intervals at each time point for the selumetinib difference versus placebo (2-sided 90% CIs) should be less than 10ms.</non_inferiority_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.4</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.0</ci_lower_limit>
            <ci_upper_limit>1.3</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>47 evaluable volunteers gives 90% power to show non-inferiority of selumetinib versus placebo across all 10 post-dose time points, using paired T-test, 1-sided alpha=0.05 and assuming a true difference of 3 msec.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>All one-sided 95% confidence intervals at each time point for the selumetinib difference versus placebo (2-sided 90% CIs) should be less than 10ms.</non_inferiority_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>9.2</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>7.6</ci_lower_limit>
            <ci_upper_limit>10.8</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in QTcF</title>
        <description>Change from baseline in QTcF at 1 hour 30 min (msec)</description>
        <time_frame>1 hour 30 min</time_frame>
        <population>All patients who had evaluable pharmacodynamic data available for at least one treatment group were included in the PD analysis set</population>
        <group_list>
          <group group_id="O1">
            <title>Moxifloxacin</title>
            <description>Moxiflxacin 400 mg (open label)</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Selumetinib placebo (3 capsules)</description>
          </group>
          <group group_id="O3">
            <title>Selumetinib</title>
            <description>Selumetinib 75mg bs (3x25mg capsules)</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in QTcF</title>
          <description>Change from baseline in QTcF at 1 hour 30 min (msec)</description>
          <population>All patients who had evaluable pharmacodynamic data available for at least one treatment group were included in the PD analysis set</population>
          <units>msec</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <units_analyzed>Participants</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="50"/>
                <count group_id="O2" value="49"/>
                <count group_id="O3" value="50"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>change from baseline</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="50"/>
                <count group_id="O2" value="49"/>
                <count group_id="O3" value="50"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.1" lower_limit="6.6" upper_limit="9.6"/>
                    <measurement group_id="O2" value="-1.8" lower_limit="-3.3" upper_limit="-0.2"/>
                    <measurement group_id="O3" value="-0.9" lower_limit="-2.4" upper_limit="0.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>47 evaluable volunteers gives 90% power to show non-inferiority of selumetinib versus placebo across all 10 post-dose time points, using paired T-test, 1-sided alpha=0.05 and assuming a true difference of 3 msec.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>All one-sided 95% confidence intervals at each time point for the selumetinib difference versus placebo (2-sided 90% CIs) should be less than 10ms.</non_inferiority_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.9</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.7</ci_lower_limit>
            <ci_upper_limit>2.5</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>47 evaluable volunteers gives 90% power to show non-inferiority of selumetinib versus placebo across all 10 post-dose time points, using paired T-test, 1-sided alpha=0.05 and assuming a true difference of 3 msec.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>All one-sided 95% confidence intervals at each time point for the selumetinib difference versus placebo (2-sided 90% CIs) should be less than 10ms.</non_inferiority_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>9.9</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>8.3</ci_lower_limit>
            <ci_upper_limit>11.5</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in QTcF</title>
        <description>Change from baseline in QTcF at 2 hours (msec)</description>
        <time_frame>2 hours</time_frame>
        <population>All patients who had evaluable pharmacodynamic data available for at least one treatment group were included in the PD analysis set</population>
        <group_list>
          <group group_id="O1">
            <title>Moxifloxacin</title>
            <description>Moxiflxacin 400 mg (open label)</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Selumetinib placebo (3 capsules)</description>
          </group>
          <group group_id="O3">
            <title>Selumetinib</title>
            <description>Selumetinib 75mg bs (3x25mg capsules)</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in QTcF</title>
          <description>Change from baseline in QTcF at 2 hours (msec)</description>
          <population>All patients who had evaluable pharmacodynamic data available for at least one treatment group were included in the PD analysis set</population>
          <units>msec</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <units_analyzed>Participants</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="50"/>
                <count group_id="O2" value="49"/>
                <count group_id="O3" value="50"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>change from baseline</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="50"/>
                <count group_id="O2" value="49"/>
                <count group_id="O3" value="50"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.9" lower_limit="6.4" upper_limit="9.4"/>
                    <measurement group_id="O2" value="-2.3" lower_limit="-3.8" upper_limit="-0.7"/>
                    <measurement group_id="O3" value="-1.9" lower_limit="-3.4" upper_limit="-0.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>47 evaluable volunteers gives 90% power to show non-inferiority of selumetinib versus placebo across all 10 post-dose time points, using paired T-test, 1-sided alpha=0.05 and assuming a true difference of 3 msec.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>All one-sided 95% confidence intervals at each time point for the selumetinib difference versus placebo (2-sided 90% CIs) should be less than 10ms.</non_inferiority_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.4</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.2</ci_lower_limit>
            <ci_upper_limit>2.0</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>47 evaluable volunteers gives 90% power to show non-inferiority of selumetinib versus placebo across all 10 post-dose time points, using paired T-test, 1-sided alpha=0.05 and assuming a true difference of 3 msec.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>All one-sided 95% confidence intervals at each time point for the selumetinib difference versus placebo (2-sided 90% CIs) should be less than 10ms.</non_inferiority_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>10.1</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>8.5</ci_lower_limit>
            <ci_upper_limit>11.8</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in QTcF</title>
        <description>Change from baseline in QTcF at 3 hours (msec)</description>
        <time_frame>3 hours</time_frame>
        <population>All patients who had evaluable pharmacodynamic data available for at least one treatment group were included in the PD analysis set</population>
        <group_list>
          <group group_id="O1">
            <title>Moxifloxacin</title>
            <description>Moxiflxacin 400 mg (open label)</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Selumetinib placebo (3 capsules)</description>
          </group>
          <group group_id="O3">
            <title>Selumetinib</title>
            <description>Selumetinib 75mg bs (3x25mg capsules)</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in QTcF</title>
          <description>Change from baseline in QTcF at 3 hours (msec)</description>
          <population>All patients who had evaluable pharmacodynamic data available for at least one treatment group were included in the PD analysis set</population>
          <units>msec</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <units_analyzed>Participants</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="50"/>
                <count group_id="O2" value="49"/>
                <count group_id="O3" value="50"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>change from baseline</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="50"/>
                <count group_id="O2" value="49"/>
                <count group_id="O3" value="50"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.8" lower_limit="7.3" upper_limit="10.3"/>
                    <measurement group_id="O2" value="-3.2" lower_limit="-4.7" upper_limit="-1.6"/>
                    <measurement group_id="O3" value="-3.3" lower_limit="-4.8" upper_limit="-1.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>47 evaluable volunteers gives 90% power to show non-inferiority of selumetinib versus placebo across all 10 post-dose time points, using paired T-test, 1-sided alpha=0.05 and assuming a true difference of 3 msec.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>All one-sided 95% confidence intervals at each time point for the selumetinib difference versus placebo (2-sided 90% CIs) should be less than 10ms.</non_inferiority_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.2</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.8</ci_lower_limit>
            <ci_upper_limit>1.5</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>47 evaluable volunteers gives 90% power to show non-inferiority of selumetinib versus placebo across all 10 post-dose time points, using paired T-test, 1-sided alpha=0.05 and assuming a true difference of 3 msec.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>All one-sided 95% confidence intervals at each time point for the selumetinib difference versus placebo (2-sided 90% CIs) should be less than 10ms.</non_inferiority_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>11.9</param_value>
            <ci_percent>90</ci_percent>
            <ci_lower_limit>10.3</ci_lower_limit>
            <ci_upper_limit>13.6</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in QTcF</title>
        <description>Change from baseline in QTcF at 4 hours (msec)</description>
        <time_frame>4 hours</time_frame>
        <population>All patients who had evaluable pharmacodynamic data available for at least one treatment group were included in the PD analysis set</population>
        <group_list>
          <group group_id="O1">
            <title>Moxifloxacin</title>
            <description>Moxiflxacin 400 mg (open label)</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Selumetinib placebo (3 capsules)</description>
          </group>
          <group group_id="O3">
            <title>Selumetinib</title>
            <description>Selumetinib 75mg bs (3x25mg capsules)</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in QTcF</title>
          <description>Change from baseline in QTcF at 4 hours (msec)</description>
          <population>All patients who had evaluable pharmacodynamic data available for at least one treatment group were included in the PD analysis set</population>
          <units>msec</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <units_analyzed>Participants</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="50"/>
                <count group_id="O2" value="49"/>
                <count group_id="O3" value="50"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>change from baseline</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="50"/>
                <count group_id="O2" value="49"/>
                <count group_id="O3" value="50"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.6" lower_limit="7.1" upper_limit="10.1"/>
                    <measurement group_id="O2" value="-2.2" lower_limit="-3.7" upper_limit="-0.7"/>
                    <measurement group_id="O3" value="-3.7" lower_limit="-5.2" upper_limit="-2.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>47 evaluable volunteers gives 90% power to show non-inferiority of selumetinib versus placebo across all 10 post-dose time points, using paired T-test, 1-sided alpha=0.05 and assuming a true difference of 3 msec.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>All one-sided 95% confidence intervals at each time point for the selumetinib difference versus placebo (2-sided 90% CIs) should be less than 10ms.</non_inferiority_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-1.5</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-3.1</ci_lower_limit>
            <ci_upper_limit>0.2</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>47 evaluable volunteers gives 90% power to show non-inferiority of selumetinib versus placebo across all 10 post-dose time points, using paired T-test, 1-sided alpha=0.05 and assuming a true difference of 3 msec.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>All one-sided 95% confidence intervals at each time point for the selumetinib difference versus placebo (2-sided 90% CIs) should be less than 10ms.</non_inferiority_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>10.8</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>9.2</ci_lower_limit>
            <ci_upper_limit>12.5</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in QTcF</title>
        <description>Change from baseline in QTcF at 6 hours (msec)</description>
        <time_frame>6 hours</time_frame>
        <population>All patients who had evaluable pharmacodynamic data available for at least one treatment group were included in the PD analysis set</population>
        <group_list>
          <group group_id="O1">
            <title>Moxifloxacin</title>
            <description>Moxiflxacin 400 mg (open label)</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Selumetinib placebo (3 capsules)</description>
          </group>
          <group group_id="O3">
            <title>Selumetinib</title>
            <description>Selumetinib 75mg bs (3x25mg capsules)</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in QTcF</title>
          <description>Change from baseline in QTcF at 6 hours (msec)</description>
          <population>All patients who had evaluable pharmacodynamic data available for at least one treatment group were included in the PD analysis set</population>
          <units>msec</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <units_analyzed>Participants</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="50"/>
                <count group_id="O2" value="49"/>
                <count group_id="O3" value="50"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>change from baseline</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="50"/>
                <count group_id="O2" value="49"/>
                <count group_id="O3" value="50"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.7" lower_limit="3.2" upper_limit="6.2"/>
                    <measurement group_id="O2" value="-4.1" lower_limit="-5.6" upper_limit="-2.6"/>
                    <measurement group_id="O3" value="-5.9" lower_limit="-7.4" upper_limit="-4.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>47 evaluable volunteers gives 90% power to show non-inferiority of selumetinib versus placebo across all 10 post-dose time points, using paired T-test, 1-sided alpha=0.05 and assuming a true difference of 3 msec.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>All one-sided 95% confidence intervals at each time point for the selumetinib difference versus placebo (2-sided 90% CIs) should be less than 10ms.</non_inferiority_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-1.8</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-3.4</ci_lower_limit>
            <ci_upper_limit>-0.1</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>47 evaluable volunteers gives 90% power to show non-inferiority of selumetinib versus placebo across all 10 post-dose time points, using paired T-test, 1-sided alpha=0.05 and assuming a true difference of 3 msec.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>All one-sided 95% confidence intervals at each time point for the selumetinib difference versus placebo (2-sided 90% CIs) should be less than 10ms.</non_inferiority_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>8.8</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>7.1</ci_lower_limit>
            <ci_upper_limit>10.4</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in QTcF</title>
        <description>Change from baseline in QTcF at 8 hours (msec)</description>
        <time_frame>8 hours</time_frame>
        <population>All patients who had evaluable pharmacodynamic data available for at least one treatment group were included in the PD analysis set</population>
        <group_list>
          <group group_id="O1">
            <title>Moxifloxacin</title>
            <description>Moxiflxacin 400 mg (open label)</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Selumetinib placebo (3 capsules)</description>
          </group>
          <group group_id="O3">
            <title>Selumetinib</title>
            <description>Selumetinib 75mg bs (3x25mg capsules)</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in QTcF</title>
          <description>Change from baseline in QTcF at 8 hours (msec)</description>
          <population>All patients who had evaluable pharmacodynamic data available for at least one treatment group were included in the PD analysis set</population>
          <units>msec</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <units_analyzed>Participants</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="50"/>
                <count group_id="O2" value="49"/>
                <count group_id="O3" value="50"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>change from baseline</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="50"/>
                <count group_id="O2" value="49"/>
                <count group_id="O3" value="50"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.6" lower_limit="2.1" upper_limit="5.1"/>
                    <measurement group_id="O2" value="-5.3" lower_limit="-6.8" upper_limit="-3.7"/>
                    <measurement group_id="O3" value="-6.5" lower_limit="-8.0" upper_limit="-5.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>47 evaluable volunteers gives 90% power to show non-inferiority of selumetinib versus placebo across all 10 post-dose time points, using paired T-test, 1-sided alpha=0.05 and assuming a true difference of 3 msec.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>All one-sided 95% confidence intervals at each time point for the selumetinib difference versus placebo (2-sided 90% CIs) should be less than 10ms.</non_inferiority_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-1.3</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.9</ci_lower_limit>
            <ci_upper_limit>0.4</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>47 evaluable volunteers gives 90% power to show non-inferiority of selumetinib versus placebo across all 10 post-dose time points, using paired T-test, 1-sided alpha=0.05 and assuming a true difference of 3 msec.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>All one-sided 95% confidence intervals at each time point for the selumetinib difference versus placebo (2-sided 90% CIs) should be less than 10ms.</non_inferiority_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>8.9</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>7.2</ci_lower_limit>
            <ci_upper_limit>10.5</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in QTcF</title>
        <description>Change from baseline in QTcF at 12 hours (msec)</description>
        <time_frame>12 hours</time_frame>
        <population>All patients who had evaluable pharmacodynamic data available for at least one treatment group were included in the PD analysis set</population>
        <group_list>
          <group group_id="O1">
            <title>Moxifloxacin</title>
            <description>Moxiflxacin 400 mg (open label)</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Selumetinib placebo (3 capsules)</description>
          </group>
          <group group_id="O3">
            <title>Selumetinib</title>
            <description>Selumetinib 75mg bs (3x25mg capsules)</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in QTcF</title>
          <description>Change from baseline in QTcF at 12 hours (msec)</description>
          <population>All patients who had evaluable pharmacodynamic data available for at least one treatment group were included in the PD analysis set</population>
          <units>msec</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <units_analyzed>Participants</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="50"/>
                <count group_id="O2" value="49"/>
                <count group_id="O3" value="50"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>change from baseline</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="50"/>
                <count group_id="O2" value="49"/>
                <count group_id="O3" value="50"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.2" lower_limit="2.7" upper_limit="5.7"/>
                    <measurement group_id="O2" value="-3.4" lower_limit="-5.0" upper_limit="-1.9"/>
                    <measurement group_id="O3" value="-8.2" lower_limit="-9.7" upper_limit="-6.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>47 evaluable volunteers gives 90% power to show non-inferiority of selumetinib versus placebo across all 10 post-dose time points, using paired T-test, 1-sided alpha=0.05 and assuming a true difference of 3 msec.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>All one-sided 95% confidence intervals at each time point for the selumetinib difference versus placebo (2-sided 90% CIs) should be less than 10ms.</non_inferiority_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-4.7</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-6.4</ci_lower_limit>
            <ci_upper_limit>-3.1</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>47 evaluable volunteers gives 90% power to show non-inferiority of selumetinib versus placebo across all 10 post-dose time points, using paired T-test, 1-sided alpha=0.05 and assuming a true difference of 3 msec.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>All one-sided 95% confidence intervals at each time point for the selumetinib difference versus placebo (2-sided 90% CIs) should be less than 10ms.</non_inferiority_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>7.6</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>6.0</ci_lower_limit>
            <ci_upper_limit>9.3</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in QTcF</title>
        <description>Change from baseline in QTcF at 24 hours (msec)</description>
        <time_frame>24 hours</time_frame>
        <population>All patients who had evaluable pharmacodynamic data available for at least one treatment group were included in the PD analysis set</population>
        <group_list>
          <group group_id="O1">
            <title>Moxifloxacin</title>
            <description>Moxiflxacin 400 mg (open label)</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Selumetinib placebo (3 capsules)</description>
          </group>
          <group group_id="O3">
            <title>Selumetinib</title>
            <description>Selumetinib 75mg bs (3x25mg capsules)</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in QTcF</title>
          <description>Change from baseline in QTcF at 24 hours (msec)</description>
          <population>All patients who had evaluable pharmacodynamic data available for at least one treatment group were included in the PD analysis set</population>
          <units>msec</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <units_analyzed>Participants</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="50"/>
                <count group_id="O2" value="49"/>
                <count group_id="O3" value="50"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>change from baseline</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="50"/>
                <count group_id="O2" value="49"/>
                <count group_id="O3" value="50"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.4" lower_limit="0.9" upper_limit="3.9"/>
                    <measurement group_id="O2" value="-1.6" lower_limit="-3.1" upper_limit="-0.1"/>
                    <measurement group_id="O3" value="-4.1" lower_limit="-5.6" upper_limit="-2.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>47 evaluable volunteers gives 90% power to show non-inferiority of selumetinib versus placebo across all 10 post-dose time points, using paired T-test, 1-sided alpha=0.05 and assuming a true difference of 3 msec.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>All one-sided 95% confidence intervals at each time point for the selumetinib difference versus placebo (2-sided 90% CIs) should be less than 10ms.</non_inferiority_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-2.5</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-4.1</ci_lower_limit>
            <ci_upper_limit>-0.9</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>47 evaluable volunteers gives 90% power to show non-inferiority of selumetinib versus placebo across all 10 post-dose time points, using paired T-test, 1-sided alpha=0.05 and assuming a true difference of 3 msec.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>All one-sided 95% confidence intervals at each time point for the selumetinib difference versus placebo (2-sided 90% CIs) should be less than 10ms.</non_inferiority_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>4.0</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>2.4</ci_lower_limit>
            <ci_upper_limit>5.7</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>AEs were collected for up to 5 weeks, this was from the day before the first randomised treatment period (Day -1, Visit 2) until the follow-up visit.</time_frame>
      <desc>Of the 54 participants in the study, 3 did not receive Selumetinib, 3 did not receive Moxifloxacin and 4 did not receive Selumetinib Placebo (due to discontinuing the study).</desc>
      <group_list>
        <group group_id="E1">
          <title>Selumetinib</title>
          <description>Selumetinib 75mg bs (3x25mg capsules)</description>
        </group>
        <group group_id="E2">
          <title>Moxifloxacin</title>
          <description>Moxiflxacin 400 mg (open label)</description>
        </group>
        <group group_id="E3">
          <title>Placebo</title>
          <description>Selumetinib placebo (3 capsules)</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="50"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Hemorrhoids</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="50"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="51"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="51"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="50"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="51"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="51"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>Rectal hemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="51"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="50"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Hypersensitivity</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="50"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>Musculoskeletal pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="51"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="50"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="51"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="51"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>Disturbance in attention</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="51"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="50"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="51"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="50"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Blister</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="51"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>Skin irritation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="50"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 60 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Gabriella Mariani</name_or_title>
      <organization>AstraZeneca</organization>
      <phone>+44 7818 523 899</phone>
      <email>ClinicalTrialTransparency@astrazeneca.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

